title: Effects of schisandrin on transcriptional factors in lipopolysaccharide-pretreated macrophages.
abstract: Schisandrin is the main active ingredient isolated from Schisandra chinensis Baill. Recent studies have demonstrated that schisandrin exhibits anti-inflammatory effects in vivo and in vitro. In this study, we examined whether the order of lipopolysaccharide (LPS) treatment affects the mechanism of schisandrin anti-inflammatory activity. We found that the antiinflammatory mechanisms are not the same depending on whether macrophages were treated with schisandrin before or after LPS. The main difference is that inhibitor kappaBalpha (IkappaBalpha) degradation was not inhibited when macrophages were pretreated by LPS before schisandrin and was weakly inhibited when macrophages were pretreated by schisandrin before LPS.
authors.affiliation: Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul, 151-742, Korea.
authors.forename: Lian Yu
authors.initials: LY
authors.lastname: Guo
authors.forename: Tran Manh
authors.initials: TM
authors.lastname: Hung
authors.forename: Kihwan
authors.initials: K
authors.lastname: Bae
authors.forename: Sehyun
authors.initials: S
authors.lastname: Jang
authors.forename: Eun Myoung
authors.initials: EM
authors.lastname: Shin
authors.forename: Ji Won
authors.initials: JW
authors.lastname: Chung
authors.forename: Sam Sik
authors.initials: SS
authors.lastname: Kang
authors.forename: Hyun Pyo
authors.initials: HP
authors.lastname: Kim
authors.forename: Yeong Shik
authors.initials: YS
authors.lastname: Kim
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002460:Cell Line; D034242:Cyclooctanes / Q000494:pharmacology*; D051546:Cyclooxygenase 2 / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D020672:I-kappa B Proteins / Q000378:metabolism; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism; D017705:Lignans / Q000494:pharmacology*; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D051379:Mice; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D010766:Phosphorylation; D011083:Polycyclic Compounds / Q000494:pharmacology*; D013997:Time Factors; D014157:Transcription Factors / Q000378:metabolism*; D048051:p38 Mitogen-Activated Protein Kinases / Q000378:metabolism
chemical_list: D000893:Anti-Inflammatory Agents; D034242:Cyclooctanes; D020672:I-kappa B Proteins; D017705:Lignans; D008070:Lipopolysaccharides; D016328:NF-kappa B; C000606205:Nfkbia protein, mouse; D011083:Polycyclic Compounds; D014157:Transcription Factors; D000072000:NF-KappaB Inhibitor alpha; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2; D048031:JNK Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C011105:schizandrin